Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
746.46
-2.41 (-0.32%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 13, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
747,094
Open
747.74
Bid (Size)
744.50 (40)
Ask (Size)
752.00 (40)
Prev. Close
748.87
Today's Range
737.34 - 756.90
52wk Range
476.49 - 821.11
Shares Outstanding
91,779,465
Dividend Yield
0.50%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
The Science of Scale: An In-Depth Look at Regeneron Pharmaceuticals (REGN) in 2026
Today 9:35 EDT
As of today, April 13, 2026, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) stands as a titan of the biotechnology sector, representing a rare blend of scientific purity and commercial dominance. In an...
Via
Finterra
Topics
Earnings
Economy
Intellectual Property
Telix and Regeneron Announce Strategic Radiopharma Collaboration
Today 6:30 EDT
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Performance
YTD
-3.8%
-3.8%
1 Month
-1.4%
-1.4%
3 Month
-2.8%
-2.8%
6 Month
+33.8%
+33.8%
1 Year
+30.7%
+30.7%
More News
Read More
Regeneron and Telix Announce Strategic Radiopharma Collaboration
Today 6:30 EDT
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)
Today 1:00 EDT
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron (REGN): Buy, Sell, or Hold Post Q4 Earnings?
April 10, 2026
Via
StockStory
Topics
Stocks
Productivity Surge and Falling Jobless Claims: The New U.S. Labor Paradigm
April 06, 2026
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Energy
Regeneron Pharmaceuticals: The Scientific Juggernaut Navigating a High-Stakes Transformation
April 03, 2026
Via
Finterra
Topics
Economy
Intellectual Property
World Trade
Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions
April 02, 2026
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know
April 02, 2026
Via
StockStory
Topics
Government
Stocks
World Trade
EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME)
April 02, 2026
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Biotech Defies Gravity: Sarepta and Corcept Lead Midday Healthcare Rally Amidst Market Volatility
March 31, 2026
Via
MarketMinute
Topics
Economy
Intellectual Property
Stocks
Regeneron Pharmaceuticals: A Strong Contender in the Biotech Arena
↗
March 30, 2026
Via
The Motley Fool
Eli Lilly Shares Slip Despite Positive Eczema Trial Results: Why the Market Reacted Coolly
March 27, 2026
Via
MarketMinute
AstraZeneca (AZN) Shares Rally After Breakthrough Chronic Lung Disease Trial Results
March 27, 2026
Via
MarketMinute
Topics
Intellectual Property
Is Regeneron a Multimillionaire-Maker Stock?
↗
March 27, 2026
Via
The Motley Fool
Topics
Intellectual Property
Kodiak Sciences Surges 19% as Phase 3 GLOW2 Trial Delivers Vital Win for Diabetic Retinopathy Treatment
March 26, 2026
Via
MarketMinute
The Brain Barrier Broken: Inside Denali Therapeutics’ Landmark FDA Approval of AVLAYAH
March 26, 2026
Via
Finterra
Topics
Economy
Initial Public Offering
Regeneron to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2026
March 25, 2026
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)
March 24, 2026
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
This $91 Million Position Signals Conviction in a Biotech Stock Eyeing FDA Decision This Year
↗
March 20, 2026
Via
The Motley Fool
Is Eli Lilly's Weight Loss Empire in Trouble?
↗
March 13, 2026
Via
The Motley Fool
3 Profitable Stocks We Think Twice About
March 13, 2026
Via
StockStory
In 2036, Investors Will Regret Not Loading Up on This Multibagger in the Making
↗
March 12, 2026
Via
The Motley Fool
Topics
Earnings
Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients
March 09, 2026
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
2 Underrated Weight Loss Stocks to Buy Now
↗
March 08, 2026
Via
The Motley Fool
Topics
Intellectual Property
Frequently Asked Questions
Is Regeneron Pharmaceuticals publicly traded?
Yes, Regeneron Pharmaceuticals is publicly traded.
What exchange does Regeneron Pharmaceuticals trade on?
Regeneron Pharmaceuticals trades on the Nasdaq Stock Market
What is the ticker symbol for Regeneron Pharmaceuticals?
The ticker symbol for Regeneron Pharmaceuticals is REGN on the Nasdaq Stock Market
What is the current price of Regeneron Pharmaceuticals?
The current price of Regeneron Pharmaceuticals is 746.46
When was Regeneron Pharmaceuticals last traded?
The last trade of Regeneron Pharmaceuticals was at 04/13/26 04:00 PM ET
What is the market capitalization of Regeneron Pharmaceuticals?
The market capitalization of Regeneron Pharmaceuticals is 68.51B
How many shares of Regeneron Pharmaceuticals are outstanding?
Regeneron Pharmaceuticals has 69B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.